222 related articles for article (PubMed ID: 35307752)
21. Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
J Phys Chem B; 2020 Jul; 124(28):5813-5824. PubMed ID: 32603111
[TBL] [Abstract][Full Text] [Related]
22. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
23. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
Park H; Jung HY; Kim K; Kim M; Hong S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
[TBL] [Abstract][Full Text] [Related]
24. Novel anilinopyrimidine derivatives as potential EGFR
Guo Y; Gao B; Gao P; Fang L; Gou S
Bioorg Med Chem; 2022 Sep; 70():116907. PubMed ID: 35810715
[TBL] [Abstract][Full Text] [Related]
25. BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC).
Patel HM; Shaikh M; Ahmad I; Lokwani D; Surana SJ
J Biomol Struct Dyn; 2021 May; 39(8):2838-2856. PubMed ID: 32276580
[TBL] [Abstract][Full Text] [Related]
26. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
[TBL] [Abstract][Full Text] [Related]
27. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
[TBL] [Abstract][Full Text] [Related]
28. Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Jang J; To C; De Clercq DJH; Park E; Ponthier CM; Shin BH; Mushajiang M; Nowak RP; Fischer ES; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14481-14489. PubMed ID: 32510788
[TBL] [Abstract][Full Text] [Related]
29. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
[TBL] [Abstract][Full Text] [Related]
31. Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Lee HJ; Schaefer G; Heffron TP; Shao L; Ye X; Sideris S; Malek S; Chan E; Merchant M; La H; Ubhayakar S; Yauch RL; Pirazzoli V; Politi K; Settleman J
Cancer Discov; 2013 Feb; 3(2):168-81. PubMed ID: 23229345
[TBL] [Abstract][Full Text] [Related]
32. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
[TBL] [Abstract][Full Text] [Related]
33. Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC).
Karnik KS; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Wakte PS
J Biomol Struct Dyn; 2023 Jul; 41(10):4696-4710. PubMed ID: 35532095
[TBL] [Abstract][Full Text] [Related]
34. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
35. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Zhou W; Ercan D; Chen L; Yun CH; Li D; Capelletti M; Cortot AB; Chirieac L; Iacob RE; Padera R; Engen JR; Wong KK; Eck MJ; Gray NS; Jänne PA
Nature; 2009 Dec; 462(7276):1070-4. PubMed ID: 20033049
[TBL] [Abstract][Full Text] [Related]
36. Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.
Damghani T; Wittlinger F; Beyett TS; Eck MJ; Laufer SA; Heppner DE
Methods Enzymol; 2023; 685():171-198. PubMed ID: 37245901
[TBL] [Abstract][Full Text] [Related]
37. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
38. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
[TBL] [Abstract][Full Text] [Related]
39. Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy.
Liu Q; Zhou J; Gao J; Ma W; Wang S; Xing L
Biochimie; 2020 Sep; 176():128-137. PubMed ID: 32721503
[TBL] [Abstract][Full Text] [Related]
40. Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.
Ding X; Tong C; Chen R; Wang X; Gao D; Zhu L
J Mol Graph Model; 2020 May; 96():107526. PubMed ID: 31901678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
